Cldi stock price climbed to $2

CLDI stock price climbed to $2.87, initiating chatter about testing monthly highs. Chartists note that surpassing recent peaks could invite fresh buying from trend-followers. The consensus EPS estimate for the current year has increased 48.9% over the last 30 days. This means that the Wall Street analysts covering CLDI are majorly in agreement about the company's potential to report better earnings than what they predicted earlier. SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI ) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the pricing of an underwritten public offering for gross proceeds of $6 million prior to deducting underwriting commissions and offering expenses. CLDI stock price seesawing between $2.80–$2.86 suggests consolidation ahead. Traders often interpret this as a healthy base before a potential breakout attempt.